GlassScriptPhysician profile
Laura Rivers
NPI 1861984437
$6,393.98
in general payments reported to CMS, 2019-2025
29 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $255 · 2022: $1,128 · 2023: $1,235 · 2024: $1,882 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,851.35 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,670.24 | 2021-2025 | Tavneos, Otezla, Evenity |
| Abbvie INC. | $1,555.38 | 2021-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $533.97 | 2024-2025 | Tremfya, Simponi Aria |
| Boehringer Ingelheim Pharmaceuticals, INC. | $341.87 | 2022-2025 | Ofev, Spevigo, Cyltezo |
| Ucb, INC. | $334.23 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $212.58 | 2024-2025 | Orencia, Sotyktu |
| Horizon Therapeutics Plc | $205.07 | 2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $173.96 | 2024-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $144.29 | 2022-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $134.24 | 2024-2025 | |
| Pfizer INC. | $134.11 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $127.91 | 2023-2024 | Lupkynis |
| Radius Health, INC. | $127.69 | 2024-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $122.20 | 2023-2025 | Saphnelo |
| Genzyme Corporation | $105.35 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $81.64 | 2024-2025 | Isturisa, Signifor Lar |
| Chiesi USA, INC. | $61.83 | 2024-2025 | Mycapssa |
| Glaxosmithkline, LLC. | $45.44 | 2023-2024 | Benlysta |
| Xeris Pharmaceuticals, INC. | $43.38 | 2023-2025 | Recorlev |
| Novo Nordisk INC | $41.01 | 2024-2025 | Ozempic |
| Sandoz INC. | $39.14 | 2023-2024 | Hyrimoz |
| Corcept Therapeutics | $30.58 | 2024 | Korlym |
| Insulet Corporation | $23.69 | 2025 | Omnipod |
| Kiniksa Pharmaceuticals International, Plc | $21.60 | 2024 | Arcalyst |
| Sequel Med Tech, LLC | $18.84 | 2025 | Twiist |
| Sanofi-Aventis U.S. LLC | $18.23 | 2024 | |
| Alexion Pharmaceuticals, INC. | $17.79 | 2025 | Strensiq |
| Genentech USA, INC. | $14.86 | 2023 | Actemra |
| Medtronic, INC. | $12.86 | 2023 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Rivers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.